Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RAF1 contributes to cell proliferation and STAT3 activation in colorectal cancer independently of microsatellite and KRAS status.

Oncogene - 1 May 2023

Dorard Coralie, Madry Claire, Buhard Olivier, Toifl Stefanie, Didusch Sebastian, Ratovomanana Toky, Letourneur Quentin, Dolznig Helmut, Garnett Mathew J, Duval Alex, Baccarini Manuela

Abstract excerpt

More than 30% of all human cancers are driven by RAS mutations and activating KRAS mutations are present in 40% of colorectal cancer (CRC) in the two main CRC subgroups, MSS (Microsatellite Stable) and MSI (Microsatellite Instable). Studies in RAS-driven tumors have shown essential roles of the RAS effectors RAF and specifically of RAF1, which can be dependent or independent of RAF's ability to activate the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Proliferation
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Microsatellite Instability

Share to Microsatellite Repeats

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Share to STAT3 Transcription Factor

Source

Open in PubMed Open full text

Identifiers

PMID: 37020037
DOI: 10.1038/s41388-023-02683-w
PMCID: PMC10181936

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RAF1 contributes to cell proliferation and STAT3 activation in colorectal cancer independently of microsatellite and KRAS status.PMID 37020037Read ↗

Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance.Semantic proximity Read ↗

Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants.Semantic proximity Read ↗

Raf: a strategic target for therapeutic development against cancer.Semantic proximity Read ↗

A molecular signature for oncogenic BRAF in human colon cancer cells is revealed by microarray analysis.Semantic proximity Read ↗

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studiesSemantic proximity Read ↗

Targeting BRAF aberrations in advanced colorectal carcinoma: from bench to bedside.Semantic proximity Read ↗

Translational relevance of SOS1 targeting for KRAS-mutant colorectal cancer.Semantic proximity Read ↗

Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications.Semantic proximity Read ↗

Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancerSemantic proximity Read ↗

RAF1 facilitates KIT signaling and serves as a potential treatment target for gastrointestinal stromal tumor.Semantic proximity Read ↗

Biological and therapeutic implications of RKIP in Gastrointestinal Stromal Tumor (GIST): an integrated transcriptomic and proteomic analysisSemantic proximity Read ↗

Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.